Fatigue in Patients with Newly Diagnosed Inflammatory Bowel Disease: Results from a Prospective Inception Cohort, the IBSEN III Study.

"Conflict of Interest B.C.O., C.L., G.H.H., G.P., I.J., M.H., R.O., R.B.C., S.V., M.B.B., Ø.H., V.S., T.B.A., M.C.S., T.B., L.P.J.J., and K.A.H. declare that they have no conflicts of interest. M.L.H. received investigator-initiated research grants from Takeda, Pfizer, Tillotts, Ferring, and Janssen. M.L.H. served as the speaker honoraris for Takeda, Tillotts, Ferring, AbbVie, and Meda. M.L.H. received support from the advisory board of Takeda, AbbVie, and MSD. V.A.K. received consultant fees from Janssen-Cilag. V.A.K. also received advisory board and consultant fees from Takeda. The advisory board of Tillotts Pharma supported V.A.K. A.W.M. received an unrestricted research grant from Takeda. T.E.D. is a speaker, consultant, and advisory board member for AbbVie, Ferring, Pfizer, Pharmacosmos, Tillotts, and Vifor Pharma. T.E.D. is also a recipient of unrestricted research grants from AbbVie and Pharmacosmos. S.O.F. has received personal fees from Takeda, Galapagos, Jansen-Cilag, Abbvie, Pharmacosmos, and Bristol-Myers-Squibb."

"Funding This work was supported by the Østfold Hospital Trust. In addition, the IBSEN III study was supported by an investigator-initiated research grant from Takeda Pharmaceuticals and non-restricted research grants from Ferring Pharmaceuticals, Pfizer, Tillotts Pharma, the Dam Foundation, and the Southeastern Health Authorities in Norway. The funding bodies played no role in the design of the study; collection, analysis, and interpretation of data; or writing of the manuscript."